Spinocerebellar Ataxias Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis
- Ankit Nigam
- Feb 2, 2021
- 3 min read
(Albany, US) DelveInsight launched its new report on Spinocerebellar Ataxias - Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight's " Spinocerebellar Ataxias - Market Insights, Epidemiology, and Market Forecast-2030 " report delivers an in-depth understanding of the Spinocerebellar Ataxias , historical and forecasted epidemiology as well as the Spinocerebellar Ataxias market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
1. According to DelveInsight, the market size of Spinocerebellar Ataxia was USD 30.28 million in 2017.
2. Spinocerebellar Ataxia total prevalent population in the seven major markets was 42,043 in 2017.
3. Even the most common form of Spinocerebellar Ataxia in US populations (Spinocerebellar Ataxia3) is likely to test negative more than 99% of the time in a patient displaying ataxia without a family history.
4. The United States is the second highest percentage of prevalent cases.
5. Spain has the least percentage of prevalent cases.
1. Spinocerebellar Ataxia market report covers a descriptive overview and comprehensive insight of the Spinocerebellar Ataxia epidemiology and Spinocerebellar Ataxia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Spinocerebellar Ataxia market report provides insights on the current and emerging therapies.
3. Spinocerebellar Ataxia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Spinocerebellar Ataxia market report offers an edge that will help in developing business strategies by understanding trends moulding and leading the Spinocerebellar Ataxia market.
Request for free sample report: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
Spinocerebellar Ataxia (SCA) is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.
Genetically, the SCAs fall into two major groups: those caused by dynamic repeat expansion mutations (repeat expansion SCAs) and those caused by nonrepeating mutations. Further, repeat expansions are also a major cause of non-SCA inherited neurological diseases. There are at least 12 repeat expansion SCAs. Six of these diseases—SCA1, SCA2, SCA3/Machado–Joseph disease, SCA6, SCA7, and SCA17 are caused by translated CAG repeat expansion mutations that encode stretches of pure glutamine in the respective disease proteins; thesediseases are thus referred to as polyglutamine SCAs.
As per DelveInsight’s estimates, SCA3 was the second most common subtype of Spinocerebellar Ataxia after others (including all the subtypes other than taken into consideration in the DelveInsight’s forecast model) in the United States, Germany, France, the United Kingdom and Japan. However, in Italy SCA2 was the second most common subtype after others. Also, in Spain the scenario was a bit different with SCA3 being the most common subtype.
Request for free sample report: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
"Among the European five countries, Germany had the highest prevalent population of SCA, followed by the France, United Kingdom and Italy."
· Biohaven Pharmaceuticals
· Kissei Pharmaceuticals
· IntraBio
· Steminent Biotherapeutics
And Many More
The launch of the emerging therapies is expected to significantly impact the Spinocerebellar Ataxia treatment scenario in the upcoming years: -
· Troriluzole (BHV-4157)
· KPS-0373 (Rovatirelin)
· IB1001
· Stemchymal
And Many More
Request for free sample report: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
1. Key Insights 2. Spinocerebellar Ataxia Market Overview at a Glance 3. Spinocerebellar Ataxia Disease Background and Overview 4. Spinocerebellar Ataxia Epidemiology and Patient Population 5. Country Wise-Epidemiology of Spinocerebellar Ataxia 5.1. United States 5.2. EU5 Countries 5.3. Germany 5.4. France 5.5. Italy 5.6. Spain 5.7. United Kingdom 5.8. Japan 6. Spinocerebellar Ataxia Treatments 7. Unmet Needs 8. Spinocerebellar Ataxia Emerging Therapies 8.1. Troriluzole: Biohaven Pharmaceuticals 8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical 9. Other Promising Candidates 9.1. IB1001: IntraBio 9.2. Stemchymal: Steminent Biotherapeutics 10. Spinocerebellar Ataxia 7 Major Market Analysis 11. The United States Market Outlook 11.1.United States Market Size 12. EU-5 Countries: Market Outlook 12.1.Germany 12.2. France 12.3. Italy 12.4. Spain 12.5. The United Kingdom 12.6.Japan: Market Outlook 12.7.Japan Market Size 13. Market Drivers 14. Market Barriers 15. Appendix 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
Related reports:
DelveInsight's 'Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Spinocerebellar Ataxia (SCA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
"Spinocerebellar Ataxias Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Spinocerebellar Ataxias market.
Comments